Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury: Toronto Wednesday, November 13, 2024, 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback